Abstract
Animal studies were done using an in vivo dogmodel to examine the possible mechanism for theesophageal adverse events reported with alendronatesodium tablets. These studies showed that under low pHconditions alendronate sodium can cause esophagealirritation. No esophageal irritation occurred at pH 3.5or higher where the drug exists primarily as the sodiumsalt. The animal studies also showed that alendronate sodium can exacerbate preexisting esophagealdamage. Exposure of the esophageal mucosa for aprolonged period to alendronate sodium tablet can alsocause mild esophageal irritation. These findings suggest that the esophageal irritation in patientstaking Fosamax can be from prolonged contact with thetablet, reflux of acidic gastric contents withalendronate sodium, and exacerbation of preexistingesophageal damage. The findings also suggest that otherbisphosphonates can cause esophageal injury undersimilar conditions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Liberman UA, Weiss SA, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Farus M, Seeman E, Recker RR, Capizi T, Santora AC, Lombardi A, Shaw R, Hirsch LJ, Karpf DB: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443, 1995
Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Grenant HK, Haskell WL, Marcus R, OH SM, Torner JR, Quandt SA, Reiss TF, Ensrud KE: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535- 1541, 1996
Didronel (etidronate disodium): US Physicians's Circular, Procter and Gamble Pharmaceuticals, The Physicians's Desk Reference 1996, pp. 1984-1986
Saunders RL Jr: Appearance of a gastric ulcer during diphosphonate therapy in a woman with CRST syndrome. South Med J 70:1327-1329, 1977
Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong V, Egan KS, O'Fallon WM, Riggs BL: Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporosis Int 4:320-322, 1994
Reginster JYL: Oral tiludronate: Pharmacological properties and potential use fulness in Pagets's disease of bone and osteoporosis. Bone 13:351-354, 1992
De Grouen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tollotson S, Seleznick MJ, Pinkas H, Wang KK: Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021, 1996
Olovson GS, Bjorkman JA, Ek L, Hauu N: The ulcerogenic effect on the esophagus of three ß-adrenoceptor antagonists, investigated in a new porcine esophagus test model. Acta Pharmacol Toxicol 53:385-391, 1983
Ryrfeldt A, Norbeck K, Reiland S, Moldeus P: Drug-induced esophageal lesions studied in vitro. Acta Physiol Scand Suppl 592:73-82, 1990
Bozymski EM, Isaacs KL: Medications reported to cause esophageal damage. InT Yamada (ed). Textbook of Gastroenterology, 2nd ed., Vol. 1. Philadelphia, JB Lippincott, 1995, pp 1283-1301
Rights and permissions
About this article
Cite this article
Peter, C.P., Handt, L.K. & Smith, S.M. Esophageal Irritation due to Alendronate Sodium Tablets (Possible Mechanisms). Dig Dis Sci 43, 1998–2002 (1998). https://doi.org/10.1023/A:1018894827961
Issue Date:
DOI: https://doi.org/10.1023/A:1018894827961